Jan 15 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS’ SERLOPITANT GRANTED BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR THE TREATMENT OF PRURITUS ASSOCIATED WITH PRURIGO NODULARIS.MENLO THERAPEUTICS INC - DATA FROM PRURIGO NODULARIS TRIALS EXPECTED BY Q1 OF 2020..
Full Article
Menlo Therapeutics Inc ::MENLO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE VIEW $-0.89 -- THOMSON REUTERS I/B/E/S.NEW PHASE 2 CLINICAL TRIAL IN CHRONIC PRURITUS OF UNKNOWN ORIGIN EXPECTED TO START IN Q4 2018.AS OF SEPTEMBER 30, 2018, MENLO HAD $152.7 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.
Full Article
Oct 8 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS ANNOUNCES RESULTS FROM A PHASE 2 CLINICAL TRIAL OF SERLOPITANT FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH.MENLO THERAPEUTICS INC - SERLOPITANT FAILS TO DEMONSTRATE EFFICACY RELATIVE TO PLACEBO ON PRIMARY AND SECONDARY ENDPOINTS.MENLO THERAPEUTICS INC - SERLOPITANT WAS WELL-TOLERATED IN STUDY.MENLO THERAPEUTICS INC - TREATMENT RELATED ADVERSE EVENTS OCCURRED AT COMPARABLE RATES IN SERLOPITANT AND PLACEBO TREATED GROUPS.MENLO THERAPEUTICS - PHASE 2 CLINICAL TRIAL OF SERLOPITANT TO TREAT PRURITUS ASSOCIATED WITH PSORIASIS IS FULLY ENROLLED, DATA EXPECTED IN DEC 2018.MENLO THERAPEUTICS - CURRENTLY ENROLLING PATIENTS IN 2 PHASE 3 TRIALS TO EVALUATE SERLOPITANT AS TREATMENT FOR PRURITUS ASSOCIATED WITH PRURIGO NODULARIS.MENLO THERAPEUTICS - DATA FROM 2 TRIALS TO EVALUATE SERLOPITANT AS TREATMENT FOR PRURITUS ASSOCIATED WITH PRURIGO NODULARIS EXPECTED IN FIRST HALF OF 2020.MENLO THERAPEUTICS - PLAN TO INITIATE PHASE 2 CLINICAL TRIAL IN PATIENTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN IN 2018, EXPECT RESULTS IN FIRST HALF OF 2020.
Full Article
Aug 1 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.36.Q2 EARNINGS PER SHARE VIEW $-0.79 -- THOMSON REUTERS I/B/E/S.
Full Article
May 9 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.72.LOWERING ITS OPERATING EXPENSE GUIDANCE FOR FULL YEAR 2018 TO A RANGE OF APPROXIMATELY $68.0 MILLION TO $78.0 MILLION.
Full Article
April 24 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS - CO'S PARTNERS FOR COMMERCIALIZATION OF SERLOPITANT IN JAPAN, INFORMED DECISION TO HALT JAPANESE PHASE 2 CLINICAL TRIAL OF SERLOPITANT.MENLO SAYS JT TORII HAS INDICATED THEY ARE REEVALUATING THEIR SERLOPITANT DEVELOPMENT PROGRAM BASED UPON EVOLVING COMMERCIAL CONSIDERATIONS IN JAPAN.MENLO THERAPEUTICS INC - BASED UPON COMMUNICATION WITH JT TORII, CO EXPECTS JT TORII LICENSE AGREEMENT FOR SERLOPITANT WILL ULTIMATELY BE TERMINATED.
Full Article
Jan 24 (Reuters) - Menlo Therapeutics Inc ::ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF COMMON STOCK.SAYS INITIAL PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.
Full Article
Jan 23 (Reuters) - Menlo Therapeutics Inc ::MENLO THERAPEUTICS INC NOW SEES IPO OF 6.5 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $16.00 AND $17.00 PER SHARE - SEC FILING.MENLO THERAPEUTICS INC SAYS IT HAD PREVIOUSLY EXPECTED IPO OF 5.67 MILLION SHARES OF COMMON STOCK PRICED BETWEE $14.00 AND $16.00 PER SHARE.
Full Article
Earnings vs. 
Estimates